Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

NICE rejects bosutinib for chronic myeloid leukaemia

By News team

Patients with previously treated chronic myeloid leukaemia (CML) will not be prescribed bosutinib on the NHS after the National Institute for Health and Care Excellence recommended against its use.

Even with a patient access scheme, bosutinib did not offer enough benefit to justify its price, said Andrew Dillon, NICE’s chief executive. “Although there is evidence to suggest bosutinib can be considered to be clinically effective for the treatment of CML, limitations in the evidence provided by the manufacturer meant that actual benefit compared to other treatments in terms of the estimated effect on overall survival was unclear,” he said.

Bosutinib is licensed for the treatment of adult patients with chronic phase, accelerated phase, and blast phase Philadelphia chromosome-positive chronic myelogenous leukaemia previously treated with one or more tyrosine kinase inhibitors and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options, according to the summary of product characteristics.

Patients who are already taking bosutinib will be able to continue with the medication until they and their clinician decides it is appropriate to stop, NICE added.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2013.11131069

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Sebastian Kaulitzki/Dreamstime.com

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.